ML216 Alleviates Age-Related Cardiac Fibrosis by Suppressing TGF-β1 Signaling Pathway
International Journal of Molecular Sciences · 10.04.2026 · 27 (8) · 3425
DOI: 10.3390/ijms27083425 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.04.2026. Verfasst von Wenbin Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Common Mechanism Research for Major Diseases, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sc…. Hauptthemen laut MEDLINE: Transforming Growth Factor beta1, Signal Transduction, Aging, Myocardium. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China, State Key Laboratory Special Fund.
Abstract (Originalsprache)
Cardiac fibrosis is a hallmark of cardiac aging and a major contributor to development of heart failure. However, therapeutic strategies that specifically target cardiac fibrosis remain limited. In this study, we demonstrate that small-molecule compound ML216 exerts protective effects against aging-associated or β-adrenoceptor agonist isoproterenol-induced cardiac fibrosis in vitro or in vivo. Mechanistically, ML216 inhibits transforming growth factor-β1 (TGF-β1) signaling by reducing TGF-β1 protein levels, thereby attenuating Mothers against decapentaplegic homolog (SMAD) phosphorylation and downstream induction of connective tissue growth factor (CTGF). This leads to a marked suppression of fibrotic genes Col1a1, Cnn2, and Acta2, ultimately resulting in reduced fibrosis. Additionally, the inhibition of the TGF-β1 pathway alleviates cardiomyocytes apoptosis, which may further limit inflammatory responses and contributes to the overall attenuation of cardiac fibrosis. Collectively, these findings demonstrate that ML216 mitigates cardiac fibrosis through the inhibition of TGF-β1 pathway-mediated fibrotic signaling and apoptosis, highlighting its potential as a therapeutic candidate for the treatment of cardiac fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Common Mechanism Research for Major Diseases, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences…
ORCID-Profile: Jun Li
Förderung
- National Natural Science Foundation of China
- National Key R&D Program of China
- State Key Laboratory Special Fund
Zitieren
APA
Liu, W., Cui, F., Huang, X., Liang, N., & Li, J. (2026). ML216 Alleviates Age-Related Cardiac Fibrosis by Suppressing TGF-β1 Signaling Pathway. International Journal of Molecular Sciences, 27(8), 3425. https://doi.org/10.3390/ijms27083425
Vancouver
Liu W, Cui F, Huang X, Liang N, Li J. ML216 Alleviates Age-Related Cardiac Fibrosis by Suppressing TGF-β1 Signaling Pathway. International Journal of Molecular Sciences. 2026;27(8):3425. doi:10.3390/ijms27083425
BibTeX
@article{Liu2026,
author = {Liu, Wenbin and Cui, Feng and Huang, Xiaodan and Liang, Na and Li, Jun},
title = {ML216 Alleviates Age-Related Cardiac Fibrosis by Suppressing TGF-β1 Signaling Pathway},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {8},
pages = {3425},
doi = {10.3390/ijms27083425}
}
EUVIMED